Posted inBiotechnology
Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to…
Posted inGenetics
Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, inside the company’s robotics lab in Suzhou, China.[Insilico Medicine] Insilico Medicine will partner…
Posted inBiotechnology
Cash-strapped Alopexx reignites plans to go public via $30M IPO to fund infectious disease programs
Alopexx has resuscitated its plans for a public listing as the biotech seeks urgently needed funds to advance a pipeline…
Posted inGenetics
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
Inflammatory bowel disease (illustration). [Christoph Burgstedt/Science Photo Library/Getty Images] Though he is trained as a gastroenterologist and scientist, Frédéric Marrache,…
Posted inGenetics
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
Laura Sepp-Lorenzino, PhD Former CSOIntellia Therapeutics Panelist Laura Sepp-Lorenzino, PhD Laura Sepp-Lorenzino, PhD, is scientific advisor and former chief scientific…
Posted inGenetics
Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
Source: wildpixel/Getty Images Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center have genetically engineered CAR T cells…
Posted inGenetics
Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model
Nipah virus [RUSLANAS BARANAUSKAS / Science Photo Library / Getty Images] Nipah virus—and the closely related Hendra virus—are zoonotic pathogens…
Posted inBiotechnology
‘There’s room for multiple winners’: Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset
Amid a flurry of traditional IPOs this year, Talawar Therapeutics is taking a less-trodden path to the public markets. The…
Posted inGenetics
Circio’s circVec and Tcelltech’s nanoSMAR Technologies Combined to Generate Nextgen In vivo CAR-T and TCR-T Cells
T cells targeting cancer cells. [Luis M Molina/Getty Images] Norway-based Circio and Tcelltech, based in Germany, will collaborate using the…
Posted inBiotechnology
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a…